《Antibiotics-basel》重点专注发布Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics领域的新研究，旨在促进和传播该领域相关的新技术和新知识。鼓励该领域研究者详细地发表他们的高质量实验研究和理论结果。根据网友分享的投稿经验，平均审稿速度为 11 Weeks 。该杂志创刊至今，在Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics领域，影响力非凡，对来稿文章质量要求很高，稿件投稿过审难度很大，刊登文章的学术水平和编辑质量在同类杂志中均名列前茅。如果你想在该杂志上发表论文，你可以向编辑部提交文章，但文章必须具有重要意义并代表该领域专业的发展。我们欢迎广大同领域的研究者提交投稿。
| CiteScore | SJR | SNIP | CiteScore排名 | |||
|---|---|---|---|---|---|---|
| 7.3 | 0.92 | 1.132 | 学科类别 | 分区 | 排名 | 百分位 |
|
大类：大类：Pharmacology,ToxicologyandPharmaceutics
小类：小类：GeneralPharmacology,ToxicologyandPharmaceutics
|
Q1 | 5/80 | 94 | |||
|
大类：大类：Pharmacology,ToxicologyandPharmaceutics
小类：小类：Pharmacology(medical)
|
Q1 | 47/272 | 82 | |||
|
大类：大类：Pharmacology,ToxicologyandPharmaceutics
小类：小类：InfectiousDiseases
|
Q1 | 83/344 | 76 | |||
|
大类：大类：Pharmacology,ToxicologyandPharmaceutics
小类：小类：Biochemistry
|
Q2 | 130/438 | 70 | |||
|
大类：大类：Pharmacology,ToxicologyandPharmaceutics
小类：小类：Microbiology(medical)
|
Q2 | 46/140 | 67 | |||
|
大类：大类：Pharmacology,ToxicologyandPharmaceutics
小类：小类：Microbiology
|
Q2 | 60/182 | 67 | |||
| 按JIF指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
|---|---|---|---|---|
| 学科：INFECTIOUS DISEASES | SCIE | Q1 | 26 / 132 | 80.7 |
| 学科：PHARMACOLOGY & PHARMACY | SCIE | Q1 | 69 / 354 | 80.6 |
| 按JCI指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
|---|---|---|---|---|
| 学科：INFECTIOUS DISEASES | SCIE | Q1 | 29 / 132 | 78.41 |
| 学科：PHARMACOLOGY & PHARMACY | SCIE | Q1 | 75 / 354 | 78.95 |
文章名称
引用次数
Iron Oxide Nanoparticles for Biomedical Applications: A Perspective on Synthesis, Drugs, Antimicrobial Activity, and Toxicity
68
Antimicrobial Silver in Medicinal and Consumer Applications: A Patent Review of the Past Decade (2007-2017)
42
The Continuing Threat of Methicillin-Resistant Staphylococcus aureus
33
Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria
26
Biocidal Agents Used for Disinfection Can Enhance Antibiotic Resistance in Gram-Negative Species
24
Potential for Bacteriophage Endolysins to Supplement or Replace Antibiotics in Food Production and Clinical Care
24
Antibiotic Discovery: Where Have We Come from, Where Do We Go?
23
Bacteriophages: Protagonists of a Post-Antibiotic Era
21
Engineering of Phage-Derived Lytic Enzymes: Improving Their Potential as Antimicrobials
19
Synergistic Action of Phage and Antibiotics: Parameters to Enhance the Killing Efficacy Against Mono and Dual-Species Biofilms
18
国家/地区
发文量
TUSA
226
TItaly
173
TSpain
111
TEngland
109
TGERMANY (FED REP GER)
81
TAustralia
72
TPortugal
66
TCHINA MAINLAND
56
TFrance
55
TSouth Korea
45
